- Home
- ABUS vs CTO Comparison
ABUS vs CTO Comparison
Compare ABUS & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- CTO
- Stock Information
- Founded
- ABUS 2005
- CTO 1902
- Country
- ABUS United States
- CTO United States
- Employees
- ABUS N/A
- CTO N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- CTO Real Estate Investment Trusts
- Sector
- ABUS Health Care
- CTO Real Estate
- Exchange
- ABUS Nasdaq
- CTO Nasdaq
- Market Cap
- ABUS 711.2M
- CTO 569.2M
- IPO Year
- ABUS N/A
- CTO N/A
- Fundamental
- Price
- ABUS $4.46
- CTO $16.17
- Analyst Decision
- ABUS Strong Buy
- CTO Strong Buy
- Analyst Count
- ABUS 2
- CTO 3
- Target Price
- ABUS $5.00
- CTO $22.00
- AVG Volume (30 Days)
- ABUS 930.7K
- CTO 317.4K
- Earning Date
- ABUS 11-10-2025
- CTO 10-28-2025
- Dividend Yield
- ABUS N/A
- CTO 9.29%
- EPS Growth
- ABUS N/A
- CTO N/A
- EPS
- ABUS N/A
- CTO N/A
- Revenue
- ABUS $15,416,000.00
- CTO $140,996,000.00
- Revenue This Year
- ABUS $138.02
- CTO $21.41
- Revenue Next Year
- ABUS N/A
- CTO $8.49
- P/E Ratio
- ABUS N/A
- CTO N/A
- Revenue Growth
- ABUS 53.23
- CTO 22.26
- 52 Week Low
- ABUS $2.71
- CTO $15.07
- 52 Week High
- ABUS $5.10
- CTO $20.88
- Technical
- Relative Strength Index (RSI)
- ABUS 54.42
- CTO 51.90
- Support Level
- ABUS $4.26
- CTO $15.59
- Resistance Level
- ABUS $4.61
- CTO $16.47
- Average True Range (ATR)
- ABUS 0.20
- CTO 0.27
- MACD
- ABUS -0.01
- CTO 0.12
- Stochastic Oscillator
- ABUS 65.45
- CTO 78.65
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.